Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
7
70%
Ph phase_3
3
30%

Phase Distribution

7

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (70.0%)
Phase 33 (30.0%)

Trials by Status

terminated220%
completed880%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

NCT02892422
completedphase_1

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

NCT02333487
terminatedphase_3

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
completedphase_3

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

NCT02717195
completedphase_1

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

NCT03670082
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02892422Phase 3

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Completed
NCT02333487Phase 1

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

Completed
NCT03230864Phase 3

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Terminated
NCT02717195Phase 3

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Completed
NCT03670082Phase 1

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Completed
NCT03103646Phase 1

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Completed
NCT03241147Phase 1

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Terminated
NCT03189615Phase 1

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Completed
NCT03195946Phase 1

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

Completed
NCT02202226Phase 1

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10